Jorge Mundo, MD
Rheumatology · Caguas, PRNPI 1265593222
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,708 of the $7,037 with a category attached, or 81.1%. 16 manufacturers reported payments, led by AbbVie at 31.8% of the total.
Across 318 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$997
- Novartis$906
- Johnson & Johnson$687
- E.r. Squibb & Sons, L.L.C.$595
- PBG Puerto Rico LLC$490
- plus $1K from 10 others
What the payments were for
- Consulting fees$1,22517%
- Food & beverage$5,70881%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $2,238 |
| Amgen | 63 | $997 |
| Novartis | 52 | $906 |
| Johnson & Johnson | 30 | $687 |
| E.r. Squibb & Sons, L.L.C. | 37 | $595 |
| PBG Puerto Rico LLC | 23 | $490 |
| AstraZeneca | 20 | $365 |
| Organon | 12 | $205 |
| Mallinckrodt Hospital Products Inc. | 2 | $203 |
| Pfizer Pharmaceuticals LLC | 8 | $96 |
| Sanofi | 5 | $93 |
| GSK | 3 | $62 |
| Boehringer Ingelheim | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $20 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,037 in reported general payments places this provider in the 70th percentile of 88 rheumatology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 431 | $2,976,366 |
| Enbrel SureclickEtanercept | 228 | $1,704,898 |
| Orencia ClickjectAbatacept | 269 | $1,542,760 |
| RinvoqUpadacitinib | 227 | $1,478,596 |
| KevzaraSarilumab | 173 | $745,926 |
| Amjevita(Cf) AutoinjectorAdalimumab-Atto | 200 | $552,151 |
| EnbrelEtanercept | 68 | $512,670 |
| Humira PenAdalimumab | 64 | $450,497 |
| ProliaDenosumab | 240 | $423,094 |
| Xeljanz XrTofacitinib Citrate | 66 | $379,806 |
| BenlystaBelimumab | 70 | $334,267 |
| OrenciaAbatacept | 45 | $257,841 |
| OrenciaAbatacept/Maltose | 43 | $208,751 |
| Humira(Cf)Adalimumab | 30 | $207,115 |
| ActemraTocilizumab | 71 | $154,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $2,238 | $1,685,711257 claims |
| AmgenEnbrel, Prolia | $997 | $935,764308 claims |
| SanofiKevzara | $93 | $745,926173 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $595 | $466,59288 claims |
| GSKBenlysta | $62 | $334,26770 claims |
| OrganonHadlima, Hadlima(Cf) | $205 | $50,63449 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 88 rheumatology providers in Puerto Rico.
Other rheumatology in Caguas
- Amarilis Perez de JesusCaguas$18K
- Laisha Baez NegronCaguas$3K
- Leyda Diaz-CorreaCaguas$2K
- Lillian Bezares GomezCaguas$1K
- Ana MartinezCaguas$1K
- Radames Sierra ZoritaSan Juan$428K
- Oscar Soto RaicesSan Juan$352K
- Yvonne FontSan Juan$193K
- Paloma AlejandroSan Juan$33K
- Linnette Lopez LopezArecibo$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.